Interventional cardiology

Bioresorbable scaffolds: not quite standing up to their promise

Lessons learned from previous trials of bioresorbable vascular scaffolds (BVS) appear to have resulted in patient outcomes comparable to those in patients receiving metallic drug-eluting stents (DES). Excessive rates of adverse events driven by scaffold thrombosis have dogged previous studies of the BVS and led to the devices being taken off the market. However the ...

Already a member?

Login to keep reading.

© 2021 the limbic